NovoCure Limited (NVCR) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to NovoCure's second quarter 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star 1-1 on your touchtone telephone. Please note this call is being recorded. I would like to turn the call over to Adam Dainey, Head of Investor Relations. Please go ahead. Good morning. Good morning. Thank you. And thank you for joining us to review NovoCure's second quarter 2026 performance. I'm joined on the phone today by our Executive Chairman Bill Doyle, CEO Frank Leonard, Chief Innovation and Medical Officer Uri Weinberg, and CFO Christoph Brackmann. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Results. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA. A measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate, and material non-cash items, and best reflects the financial value generated by our business. W...